scispace - formally typeset
W

Winfried Graninger

Researcher at Medical University of Graz

Publications -  156
Citations -  9628

Winfried Graninger is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Rheumatoid arthritis & Lupus erythematosus. The author has an hindex of 47, co-authored 156 publications receiving 7764 citations. Previous affiliations of Winfried Graninger include Medical University of Vienna & University of Graz.

Papers
More filters
Journal ArticleDOI

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

TL;DR: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Journal ArticleDOI

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Martin Aringer, +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Martin Aringer, +66 more
TL;DR: These new classification criteria for systemic lupus erythematosus have excellent sensitivity and specificity, and were developed using rigorous methodology with multidisciplinary and international input.
Journal ArticleDOI

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

TL;DR: Treating-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative and it is anticipated that ‘treating- to-target’ can and will be applicable to the care of patients with SLE.
Journal ArticleDOI

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

TL;DR: Infliximab did not lead to adverse events related to an increase in SLE activity, although autoantibodies to double-stranded DNA and cardiolipin increased, as expected; this finding, coupled with the clinical improvement in the inflammatory manifestations of the disease, indicates that further study in larger controlled trials is warranted.